Table Info

Table 1.

Common STSs and benign tumors

Common STSs	Common benign tumors that are not cancers, but can start in soft tissue
(1). Liposarcomas (2). Leiomyosarcomas (3). Malignant mesenchymoma (4). Adult fibrosarcoma (5). Synovial sarcoma (6). Rhabdomyosarcoma (7). Undifferentiated pleomorphic sarcoma (UPS)/malignant fibrous histiocytoma (MFH) (8). Alveolar soft-part sarcoma (9). Angiosarcoma (10). Clear cell sarcoma (11). Desmoplastic small round cell tumor (12). Epithelioid sarcoma (13). Fibromyxoid sarcoma low-grade (14). Myxofibrosarcomas, low-grade	(1). Lipoma, lipomatosis (2). Leiomyomas (3). Lipoblastomas (4). Hibernomas (5). Lymphangiomas (6). Myxomas (7). Rhabdomyomas (8). Elastofibromas (9). Fibromas (10). Fibrous histiocytoma (11). Granular cell tumor (12). Neurofibromas (13). Neuromas (14). Schwannomas (neurilemmomas) (15). Tenosynovial giant cell tumors (also called nodular tenosynovitis) (16). Nodular fasciitis (17). Myositis ossificans (18). Hemangioma

Common STSs

Common benign tumors that are not cancers, but can start in soft tissue

(1).
Liposarcomas
(2).
Leiomyosarcomas
(3).
Malignant mesenchymoma
(4).
Adult fibrosarcoma
(5).
Synovial sarcoma
(6).
Rhabdomyosarcoma
(7).
Undifferentiated pleomorphic sarcoma (UPS)/malignant fibrous histiocytoma (MFH)
(8).
Alveolar soft-part sarcoma
(9).
Angiosarcoma
(10).
Clear cell sarcoma
(11).
Desmoplastic small round cell tumor
(12).
Epithelioid sarcoma
(13).
Fibromyxoid sarcoma low-grade
(14).
Myxofibrosarcomas, low-grade

(1).
Lipoma, lipomatosis
(2).
Leiomyomas
(3).
Lipoblastomas
(4).
Hibernomas
(5).
Lymphangiomas
(6).
Myxomas
(7).
Rhabdomyomas
(8).
Elastofibromas
(9).
Fibromas
(10).
Fibrous histiocytoma
(11).
Granular cell tumor
(12).
Neurofibromas
(13).
Neuromas
(14).
Schwannomas (neurilemmomas)
(15).
Tenosynovial giant cell tumors (also called nodular tenosynovitis)
(16).
Nodular fasciitis
(17).
Myositis ossificans
(18).
Hemangioma

Declarations

Acknowledgments

The authors would like to acknowledge Ms. Simran Shakya for helping digitally draw the figures and performing English language editing of the manuscript.

Author contributions

SS: Conceptualization, Recourses, Writing—review & editing. ELB and SC: Writing—review & editing. JS: Writing—review & editing, Conceptualization. XZ: Conceptualization, Investigation, Validation.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Hui JY. Epidemiology and etiology of sarcomas. Surg Clin North Am. 2016;96:901–14. [DOI] [PubMed]

Panagi M, Pilavaki P, Constantinidou A, Stylianopoulos T. Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness. Theranostics. 2022;12:6106–29. [DOI] [PubMed] [PMC]

Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol. 2002;20:791–6. [DOI] [PubMed]

Choi JH, Ro JY. The 2020 WHO classification of tumors of soft tissue: selected changes and new entities. Adv Anat Pathol. 2021;28:44–58. [DOI] [PubMed]

Duran-Moreno J, Kontogeorgakos V, Koumarianou A. Soft tissue sarcomas of the upper extremities: maximizing treatment opportunities and outcomes (review). Oncol Lett. 2019;18:2179–91. [DOI] [PubMed] [PMC]

Brennan MF, Antonescu CR, Moraco N, Singer S. Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Ann Surg. 2014;260:416–22. [DOI] [PubMed] [PMC]

Soydemir GP, Bahat Z, Kandaz M, Canyilmaz E, Yöney A. Prognostic factors and clinical course of extremity soft-tissue sarcomas. J Cancer Res Ther. 2020;16:903–8. [DOI] [PubMed]

Trama A, Badalamenti G, Baldi GG, Brunello A, Caira M, Drove N, et al. Soft tissue sarcoma in Italy: from epidemiological data to clinical networking to improve patient care and outcomes. Cancer Epidemiol. 2019;59:258–64. [DOI] [PubMed]

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29. [DOI] [PubMed]

10.

von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Ganjoo KN, et al. Soft tissue sarcoma, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16:536–63. [DOI] [PubMed]

11.

Ardakani AHG, Woollard A, Ware H, Gikas P. Soft tissue sarcoma: recognizing a rare disease. Cleve Clin J Med. 2022;89:73–80. [DOI] [PubMed]

12.

Yang Z, Zheng R, Zhang S, Zeng H, Li H, Chen W. Incidence, distribution of histological subtypes and primary sites of soft tissue sarcoma in China. Cancer Biol Med. 2019;16:565–74. [DOI] [PubMed] [PMC]

13.

Mack T, Purgina B. Updates in pathology for retroperitoneal soft tissue sarcoma. Curr Oncol. 2022;29:6400–18. [DOI] [PubMed] [PMC]

14.

Dangoor A, Seddon B, Gerrand C, Grimer R, Whelan J, Judson I. UK guidelines for the management of soft tissue sarcomas. Clin Sarcoma Res. 2016;6:20. [DOI] [PubMed] [PMC]

15.

Bannasch H, Eisenhardt SU, Grosu AL, Heinz J, Momeni A, Stark GB. The diagnosis and treatment of soft tissue sarcomas of the limbs. Dtsch Arztebl Int. 2011;108:32–8. [DOI] [PubMed] [PMC]

16.

Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO classification of soft tissue tumours: news and perspectives. Pathologica. 2021;113:70–84. [DOI] [PubMed] [PMC]

17.

Mayerson JL, Scharschmidt TJ, Lewis VO, Morris CD. Diagnosis and management of soft-tissue masses. J Am Acad Orthop Surg. 2014;22:742–50. [PubMed]

18.

Steinau HU, Homann HH, Drücke D, Torres A, Soimaru D, Vogt P. Resection method and functional restoration in soft tissue sarcomas of the extremities. Chirurg. 2001;72:501–13. German. [DOI] [PubMed]

19.

Venkatesan M, Richards CJ, McCulloch TA, Perks AG, Raurell A, Ashford RU; East Midlands Sarcoma Service. Inadvertent surgical resection of soft tissue sarcomas. Eur J Surg Oncol. 2012;38:346–51. [DOI] [PubMed]

20.

Lewis JJ, Leung D, Espat J, Woodruff JM, Brennan MF. Effect of reresection in extremity soft tissue sarcoma. Ann Surg. 2000;231:655–63. [DOI] [PubMed] [PMC]

21.

Fiore M, Casali PG, Miceli R, Mariani L, Bertulli R, Lozza L, et al. Prognostic effect of re-excision in adult soft tissue sarcoma of the extremity. Ann Surg Oncol. 2006;13:110–7. [DOI] [PubMed]

22.

Improving outcomes with children and young people with cancer [Internet]. Manchester: NICE; c2024 [cited 2023 May 8]. Available from: https://www.nice.org.uk/guidance/csg7

23.

Grimer RJ. Size matters for sarcomas! Ann R Coll Surg Engl. 2006;88:519–24. [DOI] [PubMed] [PMC]

24.

Igrec J, Fuchsjäger MH. Imaging of bone sarcomas and soft-tissue sarcomas. Rofo. 2021;193:1171–82. Erratum in: Rofo. 2021;193:e5. [DOI] [PubMed]

25.

Murphey MD, Senchak LT, Mambalam PK, Logie CI, Klassen-Fischer MK, Kransdorf MJ. From the radiologic pathology archives: ewing sarcoma family of tumors: radiologic-pathologic correlation. Radiographics. 2013;33:803–31. [DOI] [PubMed]

26.

de Sá Neto JL, Simão MN, Crema MD, Engel EE, Nogueira-Barbosa MH. Diagnostic performance of magnetic resonance imaging in the assessment of periosteal reactions in bone sarcomas using conventional radiography as the reference. Radiol Bras. 2017;50:176–81. [DOI] [PubMed] [PMC]

27.

Coran A, Ortolan P, Attar S, Alberioli E, Perissinotto E, Tosi AL, et al. Magnetic resonance imaging assessment of lipomatous soft-tissue tumors. In Vivo. 2017;31:387–95. [DOI] [PubMed] [PMC]

28.

Panicek DM, Gatsonis C, Rosenthal DI, Seeger LL, Huvos AG, Moore SG, et al. CT and MR imaging in the local staging of primary malignant musculoskeletal neoplasms: report of the Radiology Diagnostic Oncology Group. Radiology. 1997;202:237–46. [DOI] [PubMed]

29.

Patel DB, Matcuk GR Jr. Imaging of soft tissue sarcomas. Chin Clin Oncol. 2018;7:35. [DOI] [PubMed]

30.

Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med. 2005;353:701–11. [DOI] [PubMed]

31.

Giuliano AE, Eilber FR. The rationale for planned reoperation after unplanned total excision of soft-tissue sarcomas. J Clin Oncol. 1985;3:1344–8. [DOI] [PubMed]

32.

Koulaxouzidis G, Schwarzkopf E, Bannasch H, Stark GB. Is revisional surgery mandatory when an unexpected sarcoma diagnosis is made following primary surgery? World J Surg Oncol. 2015;13:306. [DOI] [PubMed] [PMC]

33.

Decanter G, Stoeckle E, Honore C, Meeus P, Mattei JC, Dubray-Longeras P, et al. Watch and wait approach for re-excision after unplanned yet macroscopically complete excision of extremity and superficial truncal soft tissue sarcoma is safe and does not affect metastatic risk or amputation rate. Ann Surg Oncol. 2019;26:3526–34. [DOI] [PubMed]

34.

Sacchetti F, Alsina AC, Morganti R, Innocenti M, Andreani L, Muratori F, et al. Re-excision after unplanned excision of soft tissue sarcoma: a systematic review and metanalysis. The rationale of systematic re-excision. J Orthop. 2021;25:244–51. [DOI] [PubMed] [PMC]

35.

Smolle MA, Tunn PU, Goldenitsch E, Posch F, Szkandera J, Bergovec M, et al. The prognostic impact of unplanned excisions in a cohort of 728 soft tissue sarcoma patients: a multicentre study. Ann Surg Oncol. 2017;24:1596–605. [DOI] [PubMed] [PMC]

36.

Kang S, Kim HS, Han I. Unplanned excision of extremity soft tissue sarcoma in Korea: a nationwide study based on a claims registry. PLoS One. 2015;10:e0134354. [DOI] [PubMed] [PMC]

37.

Han I, Kang HG, Kang SC, Choi JR, Kim HS. Does delayed reexcision affect outcome after unplanned excision for soft tissue sarcoma? Clin Orthop Relat Res. 2011;469:877–83. [DOI] [PubMed] [PMC]

38.

Haas RL, Delaney TF, O’Sullivan B, Keus RB, Le Pechoux C, Olmi P, et al. Radiotherapy for management of extremity soft tissue sarcomas: why, when, and where? Int J Radiat Oncol Biol Phys. 2012;84:572–80. [DOI] [PubMed]

39.

Rosenberg SA, Tepper J, Glatstein E, Costa J, Baker A, Brennan M, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg. 1982;196:305–15. [DOI] [PubMed] [PMC]

40.

Kaushal A, Citrin D. The role of radiation therapy in the management of sarcomas. Surg Clin North Am. 2008;88:629–46. [DOI] [PubMed] [PMC]

41.

Tirotta F, Sayyed R, Jones RL, Hayes AJ. Risk factors for the development of local recurrence in extremity soft-tissue sarcoma. Expert Rev Anticancer Ther. 2022;22:83–95. [DOI] [PubMed]

42.

Davis AM, O’Sullivan B, Turcotte R, Bell R, Catton C, Chabot P, et al.; Canadian Sarcoma Group; NCI Canada Clinical Trial Group Randomized Trial. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol. 2005;75:48–53. [DOI] [PubMed]

43.

Haas RL, Gronchi A, van de Sande MAJ, Baldini EH, Gelderblom H, Messiou C, et al. Perioperative management of extremity soft tissue sarcomas. J Clin Oncol. 2018;36:118–24. [DOI] [PubMed]

44.

O’Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359:2235–41. [DOI] [PubMed]

45.

Lazerges C. Soft tissue sarcomas of the forearm, wrist and hand. Hand Surg Rehabil. 2017;36:233–43. [DOI] [PubMed]

46.

Tanaka K, Ozaki T. Adjuvant and neoadjuvant chemotherapy for soft tissue sarcomas: JCOG bone and soft tissue tumor study group. Jpn J Clin Oncol. 2021;51:180–4. [DOI] [PubMed]

47.

Krikelis D, Judson I. Role of chemotherapy in the management of soft tissue sarcomas. Expert Rev Anticancer Ther. 2010;10:249–60. [DOI] [PubMed]

48.

Sleijfer S, Seynaeve C, Verweij J. Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. Oncologist. 2005;10:833–41. [DOI] [PubMed]

49.

van Oosterom AT, Mouridsen HT, Nielsen OS, Dombernowsky P, Krzemieniecki K, Judson I, et al.; EORTC Soft Tissue and Bone Sarcoma Group. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer. 2002;38:2397–406. [DOI] [PubMed]

50.

Verma S, Younus J, Stys-Norman D, Haynes AE, Blackstein M; Members of the Sarcoma Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care. Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. Cancer Treat Rev. 2008;34:339–47. [DOI] [PubMed]

51.

Bowden L, Booher RJ. The principles and technique of resection of soft parts for sarcoma. Surgery. 1958;44:963–77. [PubMed]

52.

Gerrand CH, Wunder JS, Kandel RA, O’Sullivan B, Catton CN, Bell RS, et al. Classification of positive margins after resection of soft-tissue sarcoma of the limb predicts the risk of local recurrence. J Bone Joint Surg Br. 2001;83:1149–55. [DOI] [PubMed]

53.

Tukiainen E, Böhling T, Huuhtanen R. Soft tissue sarcoma of the trunk and extremities. Scand J Surg. 2003;92:257–63. [DOI] [PubMed]

54.

Harati K, Lange K, Goertz O, Lahmer A, Kapalschinski N, Stricker I, et al. A single-institutional review of 68 patients with dermatofibrosarcoma protuberans: wide re-excision after inadequate previous surgery results in a high rate of local control. World J Surg Oncol. 2017;15:5. [DOI] [PubMed] [PMC]

55.

Smith HG, Thomas JM, Smith MJF, Hayes AJ, Strauss DC. Major amputations for extremity soft-tissue sarcoma. Ann Surg Oncol. 2018;25:387–93. [DOI] [PubMed]

56.

Clark MA, Thomas JM. Amputation for soft-tissue sarcoma. Lancet Oncol. 2003;4:335–42. [DOI] [PubMed]

57.

Götzl R, Sterzinger S, Arkudas A, Boos AM, Semrau S, Vassos N, et al. The role of plastic reconstructive surgery in surgical therapy of soft tissue sarcomas. Cancers (Basel). 2020;12:3534. [DOI] [PubMed] [PMC]

58.

Popov P, Tukiainen E, Asko-Seljaavaara S, Huuhtanen R, Virolainen M, Virkkunen P, et al. Soft tissue sarcomas of the lower extremity: surgical treatment and outcome. Eur J Surg Oncol. 2000;26:679–85. [DOI] [PubMed]